Plexxikon Inc. And Servier Signed Cardiovascular Collaboration; Payments Totaling Over $100M
NEUILLY, France & BERKELEY, Calif.--(BUSINESS WIRE)--Plexxikon Inc., a private biotechnology company, and Servier, the leading French independent pharmaceutical company, today announced a collaboration to discover novel, non-peptidic inhibitors of renin, an enzyme known to play a direct role in hypertension, renal failure and vascular disease.